AtriCure, Inc. (ATRC) Stock Analysis
Recovery setup
Healthcare · Medical Instruments & Supplies
Sell if holding. Momentum 2.5/10 is below the 5.0 floor at $27.66 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; Earnings in 5 days (event risk).
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and... Read more
Sell if holding. Momentum 2.5/10 is below the 5.0 floor at $27.66 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; Earnings in 5 days (event risk). Chart setup: Death cross but MACD improving, RSI 47. Score 5.6/10, moderate confidence.
Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 5d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 2.5/10 is below the 5.0 floor at $27.66 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; Earnings in 5 days (event risk). Chart setup: Death cross but MACD improving, RSI 47. Prior stop was $25.82. Score 5.6/10, moderate confidence.
Take-profit target: $40.67 (+47.0% upside). Prior stop was $25.82. Stop-loss: $25.82.
Earnings in 5 days (event risk); Negative momentum; Below 200-MA, MA slope -1.6%/30d (confirmed downtrend).
AtriCure, Inc. trades at a P/E of N/A (forward 74.0). TrendMatrix value score: 7.5/10. Verdict: Sell.
15 analysts cover ATRC with a consensus score of 4.1/5. Average price target: $47.
What does AtriCure, Inc. do?AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue,...
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.